Codex Genetics was incorporated in 2013 Q1 by scientists specialized in genomics and bioinformatics. Through the use of next generation sequencing, Codex has developed a cancer genetics test using latest seqeuncing technology – GENESIS. Together with our actively growing pharmacogenomics database, we provide valuable insights into the specific causes of each individual tumor, enabling clinicians to personalize treatment for cancer patients during routine oncology practice.Codex's clinical pharmacogenomics platform helps inform treatment options and predict patients'​ response to drugs, based on individual genomic information. The differences in genetic makeup between individuals can determine the relative ability to absorp, metabolise and respond to drugs, which ultimately control their effectiveness and side effects. Codex provides two clinically actionable genetic tests that targets Cancer or other FDA approved diseases with proven pharmacogenomic information, allowing clinicians to provide personalised medication in the era of "Precision Medicine"​.